AM-580 is a potent RARalpha agonist. AM580 has powerful and selective cyto-differentiating effects on acute promyelocytic leukemia cells. AM580 inhibited the wnt pathway, measured by loss of nuclear beta-catenin, suggesting partial oncogene dependence of therapy. Am580 treatment increased RARbeta and lowered the level of RARgamma, an isotype whose expression we linked with tumor proliferation. Specific activation of a single retinoic acid receptor-alpha (RARalpha), without direct and concurrent activation of RARbeta and gamma, will inhibit mammary tumor oncogenesis in murine models relevant to human cancer.
For research use only. We do not sell to patients.